Optimized timing of using infliximab in perianal fistulizing Crohn's disease

Infliximab (IFX), as a drug of first-line therapy, can alter the natural progression of Crohn’s disease (CD), promote mucosal healing and reduce complications, hospitalizations, and the incidence of surgery. Perianal fistulas are responsible for the refractoriness of CD and represent a more aggressi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:World J Gastroenterol
Main Authors: Sun, Xue-Liang, Chen, Shi-Yi, Tao, Shan-Shan, Qiao, Li-Chao, Chen, Hong-Jin, Yang, Bo-Lin
Format: Artigo
Sprog:Inglês
Udgivet: Baishideng Publishing Group Inc 2020
Fag:
Opinion Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7167413/
https://ncbi.nlm.nih.gov/pubmed/32327905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v26.i14.1554
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker